Nicolai Wagtmann, formerly vice president of research and development at Novo Nordisk A/S, has joined Innate Pharma SA in Marseilles, France as chief scientific officer. Dr Wagtmann is a pioneer of pharmacological approaches to targeting innate immunity lymphocytes both in immuno-oncology and in inflammation. His research, initiated in academia, was developed in industry through the research collaboration between Innate Pharma and Novo Nordisk.
Innate Pharma announced the appointment on 2 October 2013.
Copyright 2013 Evernow Publishing Ltd